The Oncology Drugs Market is expected to register a CAGR of 11.2% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy), and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Oncology Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Oncology Drugs Market Segmentation
Drug Class Type- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
Strategic Insights
Oncology Drugs Market Growth Drivers- Rising Incidence of Cancer: The rising number of cancer patients worldwide drives market growth for oncology drugs. Research shows cancer cases will keep growing because more people are getting older and making unhealthy choices in their daily lives. The global cancer problem grows larger which creates more need for effective cancer treatment methods. The market for cancer treatments will keep expanding because doctors find more patients with cancer each year. More people with cancer are starting treatment because doctors now find cancers sooner and diagnose them better while patients survive longer. Advances in cancer screening help doctors find diseases earlier which increases demand for precise treatments like targeted therapy and immunotherapy plus chemotherapy. Ongoing cancer research into molecular systems helps doctors create better treatment plans that work best for each patient. The discoveries allow pharmaceutical companies to produce more advanced drug types that people want now. Drug manufacturers who lead the market now have better chances to sell their targeted cancer treatments as these treatments become more effective against specific types of cancer. The market for oncology drugs will expand because cancer incidence remains high worldwide.
- Advances in Immunotherapy and Targeted Therapy: Oncology drug market growth depends heavily on recent breakthroughs in targeted therapy and immunotherapy. Immunotherapies like immune checkpoint inhibitors change how doctors treat cancer by training the immune system to attack cancer cells. Current market research shows immunotherapies will lead the oncology drugs market because they can produce long-term remission for patients with melanoma, lung cancer, and bladder cancer. Targeted therapies focus on destroying cancer cells while leaving healthy tissues unharmed which makes them more effective than classic chemotherapy methods because they produce fewer adverse effects. These medical treatments now help patients survive cancers that were once hard to treat which makes the oncology drugs market grow bigger. Scientists now understand cancer better at the molecular level which lets them create more targeted treatments that help patients live better while getting better results. Specific cancer treatments including immunotherapy and targeted therapy will claim more market share in oncology because different types of cancer need personalized care. Research advancements will lead to more effective immunotherapies and targeted therapies which will drive earnings and market development in oncology drugs.
- Increased Investment in Cancer Research and Development (R&D): The oncology drugs market grows because more money goes into cancer research projects. Public authorities, pharma companies, and research universities now invest more money in cancer science. New market predictions show that more money going into cancer research will help create better drug treatments. Research and development teams work on making current cancer drugs work better and safer plus finding medicines for diseases that have no existing treatments. Oncotherapy drug manufacturers now create targeted treatments combined with immune response enhancers and genetic-specific medicines. Scientists are working on drugs that match specific patient DNA to help patients experience better treatment results. Research and development teams are developing treatments that both work better and cost less for patients in developing countries. The market will grow as more clinical trials happen worldwide including emerging countries. Research and Development keeps advancing to bring more effective treatments which helps innovative companies grow their market share while expanding overall oncology drugs market size.
- Adoption of Personalized Medicine: The oncology drugs market will see more patients use customized medicine in the future. Thanks to scientific progress in genetics and cell science oncologists now use personalized therapy based on a patient's cancer DNA. Market data shows personalized medicine will enhance cancer treatment because it gives doctors more exact ways to treat patients. Patients benefit from personalized medicine because it attacks cancer at its molecular origin and delivers enhanced treatment results with reduced side effects. Through genetic tests and cancer marker analysis oncologists find better treatment matches for their patients to achieve treatment success. The market growth depends on developing more cancer treatments that adapt to individual patients. Businesses that specialize in making personalized cancer drugs through targeted treatments and immune therapy will take a bigger stake in the market. The market for personalized treatments will grow stronger because companion diagnostics help doctors find the right patients for specific cancer drugs. The market growth for oncology drugs depends on advancements in genetic testing and precision medicine combined with customized treatment options.
- Rise in Combination Therapies: The oncology drugs market will see more patients receive multiple drugs at once in their treatment plans. Market research shows more doctors will use combinations of chemotherapy with targeted therapies and immunotherapy to treat cancer patients. Researchers now use combination therapies more often because they help cancer patients respond better to treatment than single drugs alone. When different treatment approaches work together they attack cancer cells using different methods which makes treatment more likely to be effective. Scientists now need combination therapies because they know cancer affects different pathways in each patient. Advanced cancer patients benefit most from combination therapy because usual single-drug treatments have failed to help them. Oncology drug market growth increases because of new combination therapy approvals and clinical evidence. Drug manufacturers who develop combination therapy formulations will take more market share because healthcare professionals choose these treatments to help patients live better with improved survival rates. The evolving nature of cancer treatments requires drug developers to use combination therapies which will expand market prospects in oncology drugs.
- Growth in Immuno-Oncology Drugs: The oncology drugs market will see major progress through immuno-oncology techniques. Immunotherapies have shown effective results against different cancer types especially melanoma, non-small cell lung cancer and renal cell carcinoma through immune checkpoint inhibitors. Market projections show immuno-oncology drugs will lead oncology treatment because they help the immune system recognize and fight cancer cells. The market will continue to expand because patients with cancer need more immunotherapy treatments. Immuno-oncology therapies will reach more patients with breast and colorectal cancer which will make these treatments available to a larger group of people. As more new immuno-oncology drugs win approval manufacturers will take a larger share of the oncology treatment market. Combining immune checkpoint inhibitor therapies makes them more effective which pushes market growth forward. Research in immune modulation and cancer vaccines will help create new solutions for medical progress. The market for oncology drugs will grow rapidly because doctors worldwide are using immunotherapy as their main treatment method for cancer.
- Introduction of Biosimilars and Generic Oncology Drugs: The arrival of biosimilar medicines and generic cancer treatments creates a major market possibility. When patents for biologic oncology drugs finish their term pharmaceutical companies can create and sell biosimilar and generic versions. According to market predictions the biosimilars sector will keep growing in the oncology drugs market. The cheaper treatment options help patients who cannot pay for expensive biologic medications to get needed medical care. As biosimilar adoption expands throughout developed and developing markets the total market size will grow because these treatments offer less expensive cancer care options. More biosimilars will be available for medical use thanks to increasing approval rates from regulators. Companies that make and develop oncology biosimilars can win a large market share because healthcare providers and insurers now use these cheaper versions of biologic treatments. The market opportunity for biosimilars and generics in oncology drugs will expand as patients demand cost-effective cancer treatments.
- Development of Targeted Therapies for Rare Cancers: Developing specific cancer therapies for rare diseases offers expanding business potential in the oncology drug sector. Research into common cancers has made great strides yet rare cancer patients still have few effective treatment choices. Market research shows experts predict more medical teams will work on creating specific cancer treatments for rare types that need better care. The medical field wants targeted therapies because they treat diseases better and cause less harm. Companies working with rare cancer patients can enter a profitable field because this patient group represents a small but lucrative market. As new therapies emerge they will expand the sales of cancer drugs since more patients need better treatment methods. Companies use molecular biology techniques to find unique cancer biomarkers which they use to develop targeted drugs. When manufacturers produce and sell more specialized cancer treatments they will gain more market share which grows the overall oncology drugs market.
- Shift Toward Combination Therapies and Personalized Medicine: Combination therapies and personalized medicine offer a major market expansion path for oncology drugs. Scientists and doctors now focus on creating cancer treatments that combine several methods because they know better how cancer works at the genetic and molecular level. Market predictions show combination therapies will form a major part of cancer treatment because doctors need advanced treatments to handle difficult-to-treat cancers. Through personalized medicine doctors can create medicines that match an individual's genetic profile to get better results with less side effects. The market for oncology drugs will grow bigger because of new treatment approaches that target specific patient needs. Companies that create personalized treatments for cancer will get more market success because doctors and patients want better treatment methods. The oncology drugs market will keep growing thanks to combination therapies and personalized medicine which will remain important development priorities.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Oncology Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Oncology Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?

Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Oncology Drugs Market is estimated to witness a CAGR of 11.2% from 2025 to 2031.
The major factors driving the oncology drugs market are the rising incidence of cancer, advances in immunotherapy and targeted therapy, and increased investment in cancer research and development (R&D).
Future trends in the oncology drugs market are the adoption of personalized medicine, the rise in combination therapies, and the growth in immuno-oncology drugs.
Some of the players operating in the market are Pfizer Inc., Merck & Co., Inc., JOHNSON & JOHNSON (Janssen Global Services, LLC), Novartis AG, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AstraZeneca, AbbVie Inc., Astellas Pharma Inc., CELGENE CORPORATION.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oncology Drugs Market - By Drug Class Type
1.3.2 Oncology Drugs Market - By Indication
1.3.3 Oncology Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ONCOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ONCOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ONCOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ONCOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. ONCOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS TYPE
7.1. OVERVIEW
7.2. DRUG CLASS TYPE MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. TARGETED THERAPY
7.4.1. Overview
7.4.2. Targeted Therapy Market Forecast and Analysis
7.5. IMMUNOTHERAPY (BIOLOGIC THERAPY)
7.5.1. Overview
7.5.2. Immunotherapy (Biologic Therapy) Market Forecast and Analysis
7.6. HORMONAL THERAPY
7.6.1. Overview
7.6.2. Hormonal Therapy Market Forecast and Analysis
8. ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. STOMACH CANCER
8.4.1. Overview
8.4.2. Stomach Cancer Market Forecast and Analysis
8.5. COLORECTAL CANCER
8.5.1. Overview
8.5.2. Colorectal Cancer Market Forecast and Analysis
8.6. BREAST CANCER
8.6.1. Overview
8.6.2. Breast Cancer Market Forecast and Analysis
8.7. PROSTATE CANCER
8.7.1. Overview
8.7.2. Prostate Cancer Market Forecast and Analysis
8.8. LIVER CANCER
8.8.1. Overview
8.8.2. Liver Cancer Market Forecast and Analysis
8.9. ESOPHAGUS CANCER
8.9.1. Overview
8.9.2. Esophagus Cancer Market Forecast and Analysis
8.10. CERVICAL CANCER
8.10.1. Overview
8.10.2. Cervical Cancer Market Forecast and Analysis
8.11. KIDNEY CANCER
8.11.1. Overview
8.11.2. Kidney Cancer Market Forecast and Analysis
8.12. BLADDER CANCER
8.12.1. Overview
8.12.2. Bladder Cancer Market Forecast and Analysis
8.13. OTHERS
8.13.1. Overview
8.13.2. Others Market Forecast and Analysis
9. ONCOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oncology Drugs Market Overview
9.1.2 North America Oncology Drugs Market Forecasts and Analysis
9.1.3 North America Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.1.4 North America Oncology Drugs Market Forecasts and Analysis - By Indication
9.1.5 North America Oncology Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Oncology Drugs Market
9.1.5.1.1 United States Oncology Drugs Market by Drug Class Type
9.1.5.1.2 United States Oncology Drugs Market by Indication
9.1.5.2 Canada Oncology Drugs Market
9.1.5.2.1 Canada Oncology Drugs Market by Drug Class Type
9.1.5.2.2 Canada Oncology Drugs Market by Indication
9.1.5.3 Mexico Oncology Drugs Market
9.1.5.3.1 Mexico Oncology Drugs Market by Drug Class Type
9.1.5.3.2 Mexico Oncology Drugs Market by Indication
9.2. EUROPE
9.2.1 Europe Oncology Drugs Market Overview
9.2.2 Europe Oncology Drugs Market Forecasts and Analysis
9.2.3 Europe Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.2.4 Europe Oncology Drugs Market Forecasts and Analysis - By Indication
9.2.5 Europe Oncology Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oncology Drugs Market
9.2.5.1.1 Germany Oncology Drugs Market by Drug Class Type
9.2.5.1.2 Germany Oncology Drugs Market by Indication
9.2.5.2 France Oncology Drugs Market
9.2.5.2.1 France Oncology Drugs Market by Drug Class Type
9.2.5.2.2 France Oncology Drugs Market by Indication
9.2.5.3 Italy Oncology Drugs Market
9.2.5.3.1 Italy Oncology Drugs Market by Drug Class Type
9.2.5.3.2 Italy Oncology Drugs Market by Indication
9.2.5.4 Spain Oncology Drugs Market
9.2.5.4.1 Spain Oncology Drugs Market by Drug Class Type
9.2.5.4.2 Spain Oncology Drugs Market by Indication
9.2.5.5 United Kingdom Oncology Drugs Market
9.2.5.5.1 United Kingdom Oncology Drugs Market by Drug Class Type
9.2.5.5.2 United Kingdom Oncology Drugs Market by Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oncology Drugs Market Overview
9.3.2 Asia-Pacific Oncology Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.3.4 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Indication
9.3.5 Asia-Pacific Oncology Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oncology Drugs Market
9.3.5.1.1 Australia Oncology Drugs Market by Drug Class Type
9.3.5.1.2 Australia Oncology Drugs Market by Indication
9.3.5.2 China Oncology Drugs Market
9.3.5.2.1 China Oncology Drugs Market by Drug Class Type
9.3.5.2.2 China Oncology Drugs Market by Indication
9.3.5.3 India Oncology Drugs Market
9.3.5.3.1 India Oncology Drugs Market by Drug Class Type
9.3.5.3.2 India Oncology Drugs Market by Indication
9.3.5.4 Japan Oncology Drugs Market
9.3.5.4.1 Japan Oncology Drugs Market by Drug Class Type
9.3.5.4.2 Japan Oncology Drugs Market by Indication
9.3.5.5 South Korea Oncology Drugs Market
9.3.5.5.1 South Korea Oncology Drugs Market by Drug Class Type
9.3.5.5.2 South Korea Oncology Drugs Market by Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oncology Drugs Market Overview
9.4.2 Middle East and Africa Oncology Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.4.4 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Indication
9.4.5 Middle East and Africa Oncology Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oncology Drugs Market
9.4.5.1.1 South Africa Oncology Drugs Market by Drug Class Type
9.4.5.1.2 South Africa Oncology Drugs Market by Indication
9.4.5.2 Saudi Arabia Oncology Drugs Market
9.4.5.2.1 Saudi Arabia Oncology Drugs Market by Drug Class Type
9.4.5.2.2 Saudi Arabia Oncology Drugs Market by Indication
9.4.5.3 U.A.E Oncology Drugs Market
9.4.5.3.1 U.A.E Oncology Drugs Market by Drug Class Type
9.4.5.3.2 U.A.E Oncology Drugs Market by Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oncology Drugs Market Overview
9.5.2 South and Central America Oncology Drugs Market Forecasts and Analysis
9.5.3 South and Central America Oncology Drugs Market Forecasts and Analysis - By Drug Class Type
9.5.4 South and Central America Oncology Drugs Market Forecasts and Analysis - By Indication
9.5.5 South and Central America Oncology Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oncology Drugs Market
9.5.5.1.1 Brazil Oncology Drugs Market by Drug Class Type
9.5.5.1.2 Brazil Oncology Drugs Market by Indication
9.5.5.2 Argentina Oncology Drugs Market
9.5.5.2.1 Argentina Oncology Drugs Market by Drug Class Type
9.5.5.2.2 Argentina Oncology Drugs Market by Indication
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ONCOLOGY DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTELLAS PHARMA INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASTRAZENECA PLC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BRISTOL-MYERS SQUIBB COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. CELGENE CORPORATION
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. F. HOFFMANN-LA ROCHE LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JOHNSON AND JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MERCK AND CO., INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. NOVARTIS AG
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Pfizer Inc.
2. Merck & Co., Inc.
3. JOHNSON & JOHNSON (Janssen Global Services, LLC)
4. Novartis AG
5. F. Hoffmann-La Roche Ltd
6. Bristol-Myers Squibb Company
7. AstraZeneca
8. AbbVie Inc.
9. Astellas Pharma Inc.
10. CELGENE CORPORATION
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.